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Abstract
Background: Promyelocytic leukemia protein (PML) is a tumor suppressor that is highly expressed in endothelial
cells nonetheless its role in endothelial cell biology remains elusive. Tumor necrosis factor alpha (TNFα) is an
important cytokine associated with many inﬂammation-related diseases. We have previously demonstrated that TNFα
induces PML protein accumulation. We hypothesized that PML may play a role in TNFα signaling pathway. To identify
potential PML target genes and investigate the putative crosstalk between PML’s function and TNFα signaling in
endothelial cells, we carried out a microarray analysis in human primary umbilical endothelial cells (HUVECs).
Results: We found that PML and TNFα regulate common and distinct genes involved in a similar spectrum of
biological processes, pathways and human diseases. More importantly, we found that PML is required for ﬁne-tuning
of TNFα-mediated immune and inﬂammatory responses. Furthermore, our data suggest that PML and TNFα
synergistically regulate cell adhesion by engaging multiple molecular mechanisms. Our biological functional assays
exempliﬁed that adhesion of U937 human leukocytes to HUVECs is co-regulated by PML and TNFα signaling.
Conclusions: Together, our study identiﬁed PML as an essential regulator of TNFα signaling by revealing the
crosstalk between PML knockdown-mediated eﬀects and TNFα-elicited signaling, thereby providing novel insights
into TNFα signaling in endothelial cells.
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Background
Promyelocytic leukemia protein (PML) is a tumor sup-
pressor protein, originally identiﬁed as a fusion partner
of the retinoid acid receptor (RAR) gene characteristic of
chromosomal translocation involved in acute promyelo-
cytic leukemia (APL). PML is enriched in distinct nuclear
sub-domains known as PML nuclear bodies (NBs) [1].
Hitherto, more than 160 proteins have been reported to
constitutively or transiently reside in PML NBs. Recent
studies suggest that PML is involved in the regula-
tion of various cellular processes including transcrip-
tion, cell cycle, post-translational modiﬁcation, anti-viral
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responses, DNA damage repair, apoptosis, and cell adhe-
sion in response to extracellular stimuli [2-8]. In addition,
studies showed that PML protein accumulation is down-
regulated in many cancer types suggesting that PML is
a tumor suppressor [9]. A tissue proﬁling study showed
that PML is highly expressed in endothelial cells (ECs)
and tissues with inﬂammation [1], but its physiological
signiﬁcance in these contexts remains elusive.
The tumor necrosis factor alpha (TNFα), secreted
by activated immune cells including macrophages
during inﬂammation, elicits a cascade of cellular sig-
naling events in ECs [10-12], such as up-regulation of
leukocyte adhesion molecules and increased endothe-
lial permeability. TNFα was initially described as being
capable of shrinking tumor size, however later studies sug-
gested that it may stimulate tumor growth by promoting
© 2012 Cheng and Kao; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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inﬂammation [13]. Thus, pharmaceutical application of
TNFα or TNFα inhibitors in cancer treatment remains
debatable [12]. To this end, we have recently investigated
the role of PML on angiogenesis in TNFα-stimulated
ECs and showed that TNFα induces PML expression
and PML is important for TNFα-suppressed angio-
genesis [14,15]. These observations suggest that there
may be complex relationship between PML and TNFα
signaling.
To further dissect the role of PML in ECs and espe-
cially in the presence of TNFα signaling, we took an
unbiased systematic approach. We knocked down PML
by two independent siRNAs with a non-targeting siRNA
as control in the presence or absence of a mild dose of
TNFα in primary human umbilical vein endothelial cells
(HUVEC) and carried out gene expression microarray
studies. Following identiﬁcation of the signiﬁcantly altered
genes, we performed extensive functional analysis and
identiﬁed an intricate pattern of crosstalk between PML
and TNFα signaling.
Results
Identiﬁcation of PML target genes, TNFα responsive genes
and synergistically regulated genes by PML and TNFα
To identify potential PML target genes, we transiently
transfected PML targeting siRNAs into HUVECs to knock
down PML expression prior to the microarray gene
expression analyses. Because siRNAs can have oﬀ-target
eﬀects, we used two independent PML siRNAs (“siP1” and
“siP2”) targeting diﬀerent regions of PML transcripts with
duplicate samples to help eliminate false target genes. We
considered a gene to be signiﬁcantly altered in respon-
sive to PML knockdown if was identiﬁed by both siRNAs.
Thus, using > 1.5 fold and a q < 0.05 as cut-oﬀ param-
eters, we identiﬁed 705 genes up-regulated (UP) and 591
genes down-regulated (DOWN) as a result of PML knock-
down in the absence of TNFα treatment in HUVECs
(Figure 1a, the intersection of both circles, i, designated
as “siP.U-siC.U” hereinafter). Using similar parameters,
we also identiﬁed genes whose expression is signiﬁcantly
altered following 20 h of TNFα treatment in wild type cells
(a) (b)
(c) (d)
Figure 1 Venn diagrams of signiﬁcantly aﬀected genes. (a) Signiﬁcantly aﬀected genes following PML knockdown by two independent siRNAs
(siP1, siP2) compared to control siRNA (siC) in HUVECs without TNFα treatment. The intersection of both circles (i) is considered signiﬁcantly aﬀected
genes by PML knockdown (designated as “siP.U-siC.U”). (b) Comparison between TNFα responsive genes (“siC.T-siC.U”) and TNFα responsive genes
when PML was knocked down (“siP.T-siP.U”). (c) Comparison between PML-knockdown responsive genes in the absence of TNFα treatment
(i, “siP.U-siC.U” from a) and in the presence of TNFα treatment (“siP.T-siC.T”). (d) Identiﬁcation of genes interactively regulated by PML knockdown
(two siRNAs, siP1 and siP2) and TNFα treatment. The intersection of both circles (ii) is considered signiﬁcantly aﬀected interaction genes. Untreated
samples, “U”; TNFα treated samples, “T”; comparison between two samples, “-”; interaction eﬀects, “∗”. Numbers in the circles, the number of
signiﬁcantly altered genes (> 1.5 fold, q < 0.05) by the indicated comparison. Numbers in the outer box, the number of unchanged genes;
up-regulation, “up” shown in red; down-regulation, “down” shown in green.
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(Figure 1b, “siC.T-siC.U”, left circle). Our data show that
totally 440 genes were up-regulated, whereas 340 genes
were down-regulated in response to TNFα treatment
(Figure 1b, left circle). Because TNFα potently induces
PML expression [14,15], we also carried out microarray
studies in which PML was knocked down with or without
TNFα treatment. When PML was knocked down, TNFα
induced 403 genes and repressed 463 genes (Figure 1b,
“siP.T-siP.U”, right circle). Among these genes, 270 (UP)
and 195 (DOWN) are common TNFα responsive genes,
regardless of whether PML was present or not (Figure 1b,
the intersection of both circles). We identiﬁed 145 (UP)
and 211 (DOWN) genes that were responsive to PML
knockdown only in the presence of TNFα (Figure 1c,
the relative complement of “siP.U-siC.U” in “siP.T-siC.T”).
Because of the factorial design of our experiments, we
were able to estimate the interaction eﬀects of PML
knockdown and TNFα treatment in HUVECs that is des-
ignated as siP∗TNFα and calculated as siP ∗ T = (siP.T −
siC.T) − (siP.U − siC.U) or equally siP ∗ T = (siP.T −
siP.U)−(siC.T−siC.U). Similarly as in Figure 1a, we iden-
tiﬁed 166 such genes by two diﬀerent siRNAs (“siP1” and
“siP2”), of which 58 genes positively responded while 108
genes showed negative interaction eﬀect following PML
knockdown and TNFα treatment (Figure 1d, the inter-
section of both circles, ii). Full gene lists are shown in
Additional ﬁle 1.
Gene Ontology analysis of PML target genes and TNFα
responsive genes
Using the genes described in Figure 1, we carried out
functional ontology analyses and identiﬁed the biological
functions signiﬁcantly aﬀected (q < 0.01) by PML knock-
down and TNFα treatment through hypergeometric tests
using the Gene Ontology (GO) (Figure 2a–c). We found
that PML knockdown and TNFα treatment aﬀected a con-
siderable number of common biological functions. The
top 25 Gene Ontology Biological Processes (GO.BP) com-
monly aﬀected by both treatments are listed in Table 1.
Speciﬁcally both treatments aﬀected various metabolic
processes, cell communication, signal transduction, multi-
ple biosynthetic processes, gene expression, transport, and
multicellular organismal development. Full lists of signif-
icantly aﬀected gene ontology information are found in
Additional ﬁle 2.
Canonical pathway associated with PML target genes and
TNFα responsive genes
We further analyzed signiﬁcantly altered (q < 0.01)
canonical pathways deﬁned by PML knockdown and
TNFα treatment using Kyoto Encyclopedia of Genes and
Genomes (KEGG) database (Figure 2d). The top 20 (by
gene numbers) are shown in Tables 2 and 3. Consis-
tent with the GO.BP analyses, we found that the largest
category of genes (n=95) aﬀected by PML knockdown are
(a) (b)
(c) (d)
Figure 2 Functional ontology analyses of PML knockdown responsive genes and TNFα treatment aﬀected genes. The identiﬁed gene lists
were analyzed by the Hyper-Geometric test (q < 0.01) as described in Methods to identify the over-represented terms of (a) GO.BP, (b) GO.MF,
(c) GO.CC and (d) KEGG pathways aﬀected by PML knockdown (“kdPML”) and TNFα treatment (“TNFα”). Two parental GO terms were removed to
reduce redundancy of the GO term deﬁnition. GO.BP, Gene Ontology Biological Process; GO.MF, Gene Ontology Molecular Function; GO.CC, Gene
Ontology Cellular Component; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Table 1 Top 25 GO.BP aﬀected by both PML knockdown and TNFα treatment
Gene Ontology Biological Process (GO.BP)
PML Knockdown TNFα
Gene number q value Gene number q value
Cellular metabolic process 539 3.04E-116 296 9.50E-52
Primary metabolic process 527 4.97E-104 287 1.06E-44
Regulation of cellular process 449 1.71E-75 301 1.92E-60
Macromolecule metabolic process 441 1.25E-81 237 7.06E-34
Biopolymer metabolic process 433 7.96E-80 230 6.54E-32
Cellular macromolecule metabolic process 413 1.71E-78 219 1.87E-31
Cellular biopolymer metabolic process 403 4.47E-75 210 2.56E-28
Biosynthetic process 294 9.75E-49 160 3.39E-21
Cell communication 288 5.37E-52 219 2.97E-56
Cellular biosynthetic process 288 9.70E-48 155 4.47E-20
Nitrogen compound metabolic process 274 6.66E-39 144 7.73E-15
Signal transduction 260 4.09E-45 201 3.61E-51
Protein metabolic process 253 7.52E-57 141 2.06E-27
Nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process 240 9.74E-31 119 1.98E-09
Macromolecule biosynthetic process 230 5.36E-35 120 2.81E-13
Cellular protein metabolic process 229 1.32E-56 125 4.20E-26
Cellular macromolecule biosynthetic process 228 1.25E-34 117 2.02E-12
Gene expression 211 5.35E-24 118 3.60E-11
Cellular biopolymer biosynthetic process 209 3.83E-30 106 1.96E-10
Biopolymer biosynthetic process 209 5.59E-30 106 2.34E-10
Transport 201 1.57E-37 124 1.35E-23
Regulation of metabolic process 197 1.26E-21 137 3.76E-20
Multicellular organismal development 193 5.30E-36 159 7.97E-46
Regulation of cellular metabolic process 187 5.51E-20 127 1.92E-17
Regulation of macromolecule metabolic process 173 5.31E-17 121 1.72E-16
those involved in metabolic pathways (Table 2). PML is
known as a tumor suppressor, and indeed, we identiﬁed
Pathways in cancer as the second largest aﬀected category
of genes (n=39) following its knockdown. Similarly, TNFα
treatment showed thatMetabolic pathways and Pathways
in cancer were the top two aﬀected pathways (Table 3).
Our pathway analysis also suggested that PML knock-
down and TNFα treatment commonly aﬀected pathways
involved in cell communication biological process includ-
ing Cytokine-cytokine receptor interaction, Focal adhe-
sion, Regulation of actin cytoskeleton, Endocytosis, Tight
junction, Chemokine signaling pathway, Cell adhesion
molecules (CAMs), Leukocyte transendothelial migration,
and Axon guidance (Tables 2 and 3).
Implication of PML and TNFα signaling in diseases
PML is a well-deﬁned tumor suppressor; however its role
in diseases other than cancers has yet to be determined.
In addition, it is well known that endothelium actively
participates in cardiovascular and chronic inﬂammation-
related diseases. Because PML is highly expressed in ECs
and inﬂamed tissues, we suspect that PML plays a signif-
icant role in regulating the EC physiology in the patho-
genesis of EC-related diseases. Therefore, we analyzed
the signiﬁcantly altered genes using Disease Ontology
Lite (DOLite) database [16]. We found that PML tar-
get genes are signiﬁcantly associated (q < 0.01) with a
variety of human diseases (Figure 3). Consistent with its
known tumor suppressor role, we identiﬁed Cancer as the
largest category of disease associated with PML. Specif-
ically, we identiﬁed cancers of multiple organ origins
to be associated with PML expression including breast,
colon, prostate, leukemia, embryoma, liver, lung, brain,
melanoma, endometriosis, stomach, and ovarian cancers.
We also found PML to be linked to cancer metastasis
as identiﬁed by an association with Neoplasm metastasis.
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Table 2 Top 20 KEGG pathways based on gene number following PML knockdown
KEGG canonical pathway name Gene number Over-represent fold q value
Metabolic pathways 95 3.129177 2.67E-20
Pathways in cancer 39 4.257452 1.77E-12
Cell cycle 30 8.4032 1.78E-17
MAPK signaling pathway 27 3.600042 2.30E-07
Cytokine-cytokine receptor interaction 24 3.297377 4.66E-06
Focal adhesion 23 4.11424 2.30E-07
Regulation of actin cytoskeleton 23 3.847576 7.25E-07
Small cell lung cancer 20 8.4032 7.25E-12
Purine metabolism 20 4.723367 2.30E-07
Endocytosis 20 3.864573 3.69E-06
p53 signaling pathway 19 9.949875 1.71E-12
Pyrimidine metabolism 17 6.33272 3.70E-08
Tight junction 17 4.584133 3.09E-06
Natural killer cell mediated cytotoxicity 17 4.483751 3.65E-06
Chemokine signaling pathway 17 3.199343 0.000168
Cell adhesion molecules (CAMs) 15 4.044824 4.55E-05
Lysosome 14 4.398892 3.96E-05
Leukocyte transendothelial migration 14 4.25103 4.86E-05
Axon guidance 14 3.921493 0.000105
T cell receptor signaling pathway 13 4.349434 7.40E-05
Table 3 Top 20 KEGG pathways based on gene number following TNFα treatment
KEGG canonical pathway name Gene number Over-represent fold q Value
Metabolic pathways 39 2.125783 9.13E-05
Pathways in cancer 35 6.322678 5.29E-16
Cytokine-cytokine receptor interaction 33 7.502728 5.05E-17
Cell adhesion molecules (CAMs) 22 9.817002 4.87E-14
Chemokine signaling pathway 22 6.851449 5.71E-11
Focal adhesion 21 6.216256 8.39E-10
MAPK signaling pathway 20 4.412876 5.87E-07
Tight junction 17 7.585865 2.33E-09
Small cell lung cancer 16 11.12455 4.05E-11
Toll-like receptor signaling pathway 16 9.472391 3.54E-10
Regulation of actin cytoskeleton 15 4.152394 3.88E-05
Axon guidance 14 6.489322 5.87E-07
Leukocyte transendothelial migration 13 6.532169 1.44E-06
Epithelial cell signaling in Helicobacter pylori infection 12 10.55196 2.34E-08
Neurotrophin signaling pathway 12 5.649871 1.69E-05
Hematopoietic cell lineage 11 7.474308 3.16E-06
Natural killer cell mediated cytotoxicity 11 4.801016 0.000148
Endocytosis 11 3.517322 0.001595
ECM-receptor interaction 10 7.118389 1.62E-05
Antigen processing and presentation 10 6.718479 2.42E-05
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Figure 3 PML function and TNFα signaling are linked to multiple human diseases. The signiﬁcantly aﬀected genes by PML knockdown and
TNFα signaling are signiﬁcantly associated (q < 0.01) with multiple human diseases analyzed as described in Methods using a Disease Ontology
database. The diseases are sorted vertically according to the number of associated signiﬁcantly altered genes following PML knockdown. The
transformed values (−ln (q value)) of FDR adjusted p value for each category of diseases are shown in the same graph. The dashed lines indicate
−ln (q = 0.01) ≈ 4.6.
Interestingly, PML appears to be involved in several
metabolism-related diseases and cardiovascular diseases
such as Diabetes mellitus, Obesity, Atherosclerosis and
Hypertension. PML is also associated with inﬂammation
and auto-immune related diseases including Rheumatoid
arthritis, Atherosclerosis, Obesity, Polyarthritis, Asthma,
Systemic scleroderma, Ulcerative colitis, Dermatitis. Our
data also show that PML is associated with neural sys-
tem diseases including Alzheimer’s diseases, Schizophre-
nia and Parkinson’s diseases and embryonic develop-
ment disease (Congenital abnormality). Consistent with
results from GO.BP and KEGG analyses showing that
PML and TNFα signaling are involved in a similar
spectrum of biological processes and canonical path-
ways (Figure 2, Tables 2 and 3), TNFα responsive genes
are also signiﬁcantly associated (q < 0.01) with these
diseases.
PML and class I major histological complex human
leukocyte antigens
Among the signiﬁcantly aﬀected genes, we found that
a group of class I major histological complex (MHC)
human leukocyte antigens (HLAs) were down-regulated
by PML knockdown, including HLA-A (5.59 fold), HLA-
B (4.71 fold), HLA-C (1.93 fold), HLA-F (1.69 fold), and
HLA-G (1.61 fold). Interestingly, this cluster of genes is
located on chromosome 6p21.3, a region previously linked
to leukemia and other auto-immune diseases [17-22].
Other disease-associated chromosomal regions including
2q36.3–37.1, 6p21.3–22.2, 12q13–14, 12q24.31–33, and
20q11.21–23 also contains PML-knockdown responsive
genes and summarized in Table 4. These regions have
been previously linked to a variety of human health con-
ditions including multiple cancers, chronic inﬂammatory
diseases, auto-immune diseases, diabetes, cardiovascular
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Table 4 Disease-associated chromosomal regions containing PML target genes





2q37 deletion syndrome (intellectual disability, autism, short SLC16A14 0.63 0.64
2q36.3–37.1 stature, obesity, and characteristic facial features) (Casas et al. CAB39 0.42 0.58









leukemia, lymphoma, other cancers, multiple sclerosis, chronic HLA-C 0.59 0.45
inﬂammatory arthritis, type I diabetes, psoriasis, other LTB 0.65 0.65
6p21.3–22.2 autoimmue diseases. (Sawcer et al 1996, Bevan et al 2000, HCP5 0.34 0.26
Concannon et al 2005, Maleno et al 2005, Qiao et al 2007, HLA-A 0.15 0.21














12q13–14 Intimal sarcoma, lymphoma, gliomas. (Reifenberger et al 1994, BLOC1S1 2.12 1.95
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Table 4 Disease-associated chromosomal regions containing PML target genes (Continued)
RPLP0 1.92 2.05
MLEC 2.19 1.84
Teratocarcinoma, dysmorphic features and developmental DENR 2.14 2.93
delay, beckwith-wiedemann syndrome, mitochondrial FAM101A 1.77 2.08
12q24.31–33 myopathy, asthma. (Deyo et al 1998 , Casas et al 2004, ZNF664 2.84 3.49
Brasch-Andersen et al 2006, Baple et al 2010, Al-Zahrani et al STX2 3.77 3.51




20q11.21–23 Bladder cancer, type II diabetes,myocardial infarction. C20orf127 2.07 2.10
(Tanahashi et al 2006, Potter et al 2008, Sherva et al 2008) BLCAP 2.07 1.67
TGM2 7.82 7.35
C20orf129 4.15 2.82
disease and developmental defects (Additional ﬁle 3:
Figure S1). However, the link between PML-regulated
gene expression and the disease-associated chromosomal
abnormalities is currently unclear.
Crosstalk between PML knockdown and TNFα signaling
Given that TNFα potently induces PML expression, we
anticipated that TNFα and PML would regulate expres-
sion of a common sets of genes and not just common
pathways. Indeed, our microarray gene expression analy-
ses show that this is the case. Intriguingly, we also iden-
tiﬁed a group of genes (n=166) whose expressions were
interactively altered when PML was knocked down in the
presence of TNFα treatment (Figure 1d). The top 15 such
genes and their fold changes are listed in Table 5. Gene
ontology information analyses revealed that these genes
are involved in KEGG pathways includingMetabolic path-
ways, Cell cycle, p53 signaling pathway,Hematopoietic cell
lineage, Apoptosis and immune response-related KEGG
pathways such as Cytokine-cytokine receptor interaction,
Graft-versus-host disease and Type I diabetes mellitus
(Table 6).
Knockdown of PML promotes TNFα-induced inﬂammatory
response
TNFα is a cytokine that mediates inﬂammatory response
during wounding, chronic inﬂammation, and bacterial
infection. Our ﬁndings suggesting that PML is associ-
ated with inﬂammation and auto-immune related diseases
implies that PML may actively participated in TNFα-
mediated eﬀects in the inﬂammatory response. To test
this, we utilized a cluster analysis combined with the
gene functional ontology information (GO and KEGG
databases) to examine potential crosstalk between PML
and TNFα. We identiﬁed two clusters of genes signiﬁ-
cantly associated (q  1.03E − 3) with inﬂammation-
related ontology information (GO:0006955, GO:0005615,
GO:0006954, GO:0008009, GO:0006959, GO:0008083,
GO:0009887, GO:0051216 and KEGG pathway Cytokine-
cytokine receptor interaction). These genes showed a pos-
itive synergistic eﬀect between PML knockdown and
TNFα treatment (Figure 4).
We found that these two clusters of genes are mostly
induced by TNFα treatment (Figure 4a–b, columns of
“CT-CU”). The NF-κB pathway is a well-established early
activation pathway downstream of TNFα signaling dur-
ing the inﬂammatory response. Both of these two clusters
contain a large number of genes that are NF-κB acti-
vators or target genes. For example, the TNFα induced
genes, APOL3, TNFAIP1, TRAF1 are activators of NF-
κB signaling while many other genes are known NF-
κB target genes, such as CCL2, CCL5, CD69, CSF2,
CSF3, ICAM1, IL15, IL1A, IL6, IL8, IRF1, IRF7, MMP10,
NFKB1A, NFKB1E, NFKB1Z, NFKB2, PDGFB, PTGS2,
RELB, SELE, SOD2, TAP1, TNC, TNFAIP1, TNFAIP3,
TNFRSF9, TNFRSF11B. Most interestingly, we found that
PML is required for the normal expression of these TNFα-
induced genes (Figure 4a–b, columns of “PU-CU”) as
knockdown of PML decreased expression of these genes.
Since members of TNF superfamily and TNF receptor
superfamily play pivotal roles in the activation of NF-
κB pathway, we examined the expression of these genes
in the microarray and found that PML knockdown did
not signiﬁcantly aﬀect the expression of the TNF gene
or its superfamily members TNFSF7–9, 11–15, and 18,
although knockdown of PML did aﬀect expression of
TNFSF4 (2.63↑) andTNFSF10 (2.07↓).We also found that






















Table 5 Top 15 genes interactively regulated by PML knockdown and TNFα treatment
Refseq Entrez Symbol Deﬁnition siC.T-siC.U siP.T-siP.U siP.U-siC.U siP.T-siC.T siP∗T
NM 002996.3 6376 CX3CL1 Chemokine (C-X3-C motif) ligand 1 8.88 88.86 0.14 1.40 10.00
NM 006398.2 10537 UBD Ubiquitin D 7.74 73.62 0.95 9.07 9.51
NM 000450.1 6401 SELE Selectin E (endothelial adhesion molecule 1) 33.57 293.72 0.78 6.83 8.75
NM 020311.1 57007 CMKOR1 Chemokine orphan receptor 1 1.30 9.84 0.26 1.99 7.56
NM 001007595.1 388125 NLF2 Nuclear localized factor 2 1.40 8.14 0.60 3.48 5.79
NM 152851.1 64231 MS4A6A Membrane-spanning 4-domains, subfamily A, member 6A, transcript variant 3 0.18 0.99 0.23 1.27 5.51
NM 006623.2 26227 PHGDH Phosphoglycerate dehydrogenase 0.19 0.98 0.51 2.61 5.17
NM 052941.2 115361 GBP4 Guanylate binding protein 4 2.82 14.26 0.26 1.31 5.05
NM 006332.3 10437 IFI30 Interferon, gamma-inducible protein 30 1.64 8.07 0.60 2.97 4.93
NM 000963.1 5743 PTGS2 Prostaglandin-endoperoxide synthase 2 6.42 29.70 0.32 1.48 4.63
NM 004915.3 9619 ABCG1 ATP-binding cassette, sub-family G, member 1 1.02 3.74 0.34 1.25 3.68
NM 001024465.1 6648 SOD2 Superoxide dismutase 2, mitochondrial, nuclear gene encoding mitochondrial protein 14.96 54.60 0.85 3.08 3.65
NM 003046.2 6542 SLC7A2 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 25.69 93.30 0.76 2.75 3.63
NM 002970.1 6303 SAT1 Spermidine/spermine N1-acetyltransferase 1 1.01 3.56 0.62 2.18 3.53
NM 003855.2 8809 IL18R1 Interleukin 18 receptor 1 2.23 7.74 0.63 2.18 3.46
NM 017413.3 8862 APLN Apelin 1.28 0.18 3.71 0.52 0.14
NM 001255.1 991 CDC20 CDC20 cell division cycle 20 homolog (S. cerevisiae) 0.98 0.16 35.74 5.99 0.16
NM 199160.1 26468 LHX6 LIM homeobox 6 0.49 0.10 0.95 0.19 0.20
NM 001067.2 7153 TOP2A Topoisomerase II alpha 0.90 0.19 15.98 3.32 0.21
NM 005733.1 10112 KIF20A Kinesin family member 20A 0.99 0.22 8.03 1.76 0.22
NM 016242.2 51705 EMCN Endomucin 0.38 0.09 0.59 0.14 0.23
NM 004701.2 9133 CCNB2 Cyclin B2 1.04 0.25 10.86 2.53 0.24
NM 018136.2 259266 ASPM Asp (abnormal spindle)-like, microcephaly associated (Drosophila) 0.92 0.22 10.06 2.41 0.24
NM 181803.1 11065 UBE2C Ubiquitin-conjugating enzyme E2C 0.96 0.23 24.06 5.95 0.24
NM 003186.3 6876 TAGLN Transgelin 3.67 0.91 0.85 0.23 0.27
NM 015234.3 221395 GPR116 G protein-coupled receptor 116 1.04 0.29 1.07 0.30 0.28
NM 014750.3 9787 DLG7 discs, large homolog 7 (Drosophila) 1.00 0.30 6.53 1.96 0.30
NM 003981.2 9055 PRC1 Protein regulator of cytokinesis 1 0.99 0.29 9.94 2.92 0.30
NM 016359.2 51203 NUSAP1 Nucleolar and spindle associated protein 1 0.97 0.29 11.76 3.40 0.30
NM 018131.3 55165 CEP55 centrosomal protein 55kDa 1.00 0.31 9.62 2.91 0.30
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Table 6 Top KEGG pathways interactively regulated by PML knockdown and TNFα signaling
KEGG canonical pathway name Gene number Over-represent fold p Value
Metabolic pathways 9 2.29839 0.0944
Cell cycle 7 15.20184 2.92E-05
Cytokine-cytokine receptor interaction 6 6.391213 0.012504
p53 signaling pathway 3 12.18035 0.037604
Hematopoietic cell lineage 3 9.550505 0.037604
Apoptosis 3 9.443196 0.037604
Glycine, serine and threonine metabolism 2 18.67654 0.041913
Prion diseases 2 15.56379 0.053207
Graft-versus-host disease 2 13.34039 0.064162
Type I diabetes mellitus 2 12.73401 0.064162
superfamily (TNFRSF) members, including TNFRSF1B
(2.21 fold), TNFRSF10B (2.49 fold), TNFRSF10D (3.42
fold) and TNFRSF21 (3.62 fold), and down-regulated
TNFRSF10A (1.75 fold). Other TNFRSF members 1A, 4,
6B, 7–9, 10A, 10C, 11A, 11B, 12A, 13B, 13C, 14, 17–
19, 19L, and 25 were not signiﬁcantly aﬀected by PML
knockdown.
To determine the eﬀects of PML knockdown in TNFα
signaling, we compared the TNFα eﬀects without and
with PML knockdown. We found that the TNFα-induced
genes were further up-regulated when PML was knocked
down (Figure 4a–b, comparing columns between “PT-PU”
and “CT-CU”). We also examined the eﬀects of TNFα
when PMLwas knocked down and found that TNFα treat-
ment relieved or even reversed the suppression of these
clusters of genes by PML knockdown (Figure 4a–b, com-
paring columns of “PT-CT” and “PU-CU”). Therefore, we
conclude that these inﬂammatory response-related genes
are interactively regulated by PML and TNFα in a positive
manner (Figure 4a–b, column of “PxT”) and that PMLmay
have eﬀects on NF-κB activity in TNFα-treated HUVECs.
PML and TNFα signaling interactively regulates cell
adhesion in ECs
Our GO.BP and KEGG analyses suggest that PML knock-
down aﬀected Cell communication processes and the
related KEGG pathways. In-depth analyses of the genes
altered by PML knockdown showed that PML knockdown
interferes with a molecular network of genes involved in
the cell adhesion, cytoskeleton, and signaling transduction
by extracellular cytokines/chemokines (Additional ﬁle 3:
Figure S2). Because TNFα is known to activate leukocyte
adhesion to endothelial cells during inﬂammation, we sus-
pect that PML target genes and TNFα responsive genes
are involved in a coregulatory network of cell adhesion.
Indeed, by hierarchial cluster analysis we found that an
array of genes (n=182) involved in cell adhesion pathways
show interaction patterns following PML knockdown and
TNFα treatment (Figure 5a). We also identiﬁed poten-
tial regulatory mechanisms of cell adhesion by PML and
TNFα signaling through analysis of the sub-clusters of
genes in the dendritic tree identiﬁed by the hierarchial
cluster.
We identiﬁed 4 sub-clusters of genes that generally
represent 4 putative mechanisms by which PML and
TNFα regulate HUVEC adhesion pathways. In Figure 5a,
the sub-cluster annotated by the blue side bar repre-
sents a group of genes that were mostly suppressed by
PML (up-regulation by PML knockdown, red in “siP1.U-
siC.U” and “siP2.U-siC.U”). However, TNFα treatment
had a mixed eﬀects (either up- or down-regulation, red
or green in “siC.T-siC.U”) on these genes. The inter-
action eﬀects (“siP1∗T” and “siP2∗T”) mildly showed
green, which indicates that TNFα treatment had nega-
tive eﬀects on PML knockdown-induced gene expression.
The sub-cluster annotated by the red bar shows a group
of genes whose normal expression required PML (down-
regulation by PML knockdown, green in “siP1.U-siC.U”
and “siP2.U-siC.U”). TNFα treatment suppressed most
of these genes (green in “siC.T-siC.U”). For these genes,
there was little crosstalk (“siP1∗T” and “siP2∗T” showed
mostly black). The sub-cluster annotated by the green
bar are genes mostly induced by TNFα treatment (red in
“siC.T-siC.U”) but not potently aﬀected by PML knock-
down (mildly green or black in “siP1.T-siC.U” and “siP2.T-
siC.U”), except a small fraction of genes that require PML
for their normal expression (down-regulation by PML
knockdown). Although this small fraction of genes was
not very responsive to TNFα treatment alone (slightly
red in “siC.T-siC.U”), TNFα potently induced the expres-
sion of these genes after PML was knocked down (red
in “siP1.T-siP1.U” and “siP2.T-siP2.U”). The ﬁnal sub-
cluster annotated by the purple side bar are genes induced
by TNFα (red in “siC.T-siC.U”) but suppressed by PML
knockdown (green in “siP1.U-siC.U” and “siP2.U-siC.U”).
Some of these genes showed positive interaction (red in
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(a) (b) Ontology Category Name q value
(a)
GO.BP Immune response 1.13E-10
GO.CC Extracellular space 3.66E-08
GO.BP Inflammatory response 3.85E-08
GO.M F Chemokine activity 7.80E-08
GO.BP Humor alimmune response 1.36E-06
(b)
GO.M F Growth factor activity 2.60E-05
GO.BP Immune response 5.68E-05
KEGG Cytokine-cytokine receptor interaction 6.85E-05
GO.BP Organ morphogenesis 2.99E-04
GO.BP Cartilagedevelopment 1.08E-03
Figure 4 The interactive eﬀects of PML knockdown on TNFα signaling-induced inﬂammatory response. (a and b) Two clusters of genes
annotated with inﬂammation-associated ontology information were identiﬁed in a clustering analysis of the log fold change values of signiﬁcantly
aﬀected genes combined with their gene ontology information (GO and KEGG). The aﬀected categories of ontology information and the Fisher
exact test results are summarized in the table. “CT-CU”, TNFα eﬀects with control siRNA transfection; “PT-PU”, TNFα eﬀects with PML siRNAs
transfected; “PU-CU”, PML knockdown eﬀects; “PT-CT”, PML knockdown eﬀects when TNFα treated; “PxT”, the interaction eﬀects of PML knockdown
and TNFα treatment deﬁned as P × T = (PT − PU) − (CT − CU) = (PT − CT) − (PU − CU). GO, Gene Ontology database; BP, biological function;
CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Figure 5 The eﬀects of PML knockdown and/or TNFα on leukocyte:HUVEC adhesion. (a) Clustering analysis of the log change fold values of
the coregulatory network of genes signiﬁcantly aﬀected by PML knockdown and/or TNFα signaling. Using dynamicTreeCut R package as described
in Methods, 4 sub-clusters of signiﬁcantly altered genes were identiﬁed and annotated by color side bars (blue, red, green and purple respectively).
Control siRNA, “siC”; two PML siRNAs, “siP1” and “siP2”; vehicle treated samples, “U”; TNFα treated samples, “T”; minus sign of “-”, comparison between
two samples; sign of “∗”, interaction eﬀects. (b) Quantiﬁcation of the adherence of human leukocyte U937 cells on HUVECs transfected with control
siRNA (siCtrl) or two independent PML siRNAs (siPML-1 and siPML-2) without or with TNFα treatment. Two-tail unpaired t-tests: ∗, p < 0.05; ∗∗,
p < 0.01; ∗ ∗ ∗, p < 0.001.
“siP1∗T” and “siP2∗T”) and others showed negative inter-
action eﬀects (green in “siP1∗T” and “siP2∗T”) by PML
knockdown and TNFα treatment. Taken together, our
data indicate that PML and TNFα regulate HUVEC cell
adhesion in HUVEC through in an interactive manner by
regulating overlapping and distinct groups of genes.
One of the key events during leukocyte transendothelial
migration is cell adhesion, which we identiﬁed as one of
the signiﬁcantly aﬀected pathways by PML knockdown
and TNFα treatment (Tables 2 and 3). During the ini-
tial stage of leukocyte transendothelial migration, the
endothelial cells express cell adhesionmolecules to adhere
the circulating leukocytes in response to inﬂammatory
cytokines, such as TNFα. To determine whether PML
regulates cell adhesion in this process, we carried out
an in vitro cell adhesion assay (Figure 5b). We knocked
down PML by two diﬀerent siRNAs in HUVECs followed
by treatment with vehicle or TNFα for 4 h. A suspen-
sion of ﬂuorescence-labeled human leukocyte U937 cells
were added to a monolayer of HUVECs for 30 min. After
extensive washing, the adherent cells were quantiﬁed by
reading the ﬂuorescence signal retained by HUVECs. We
found that knockdown of PML modestly increased the
U937 adherence to HUVECs in the absence of TNFα
treatment (1.62 ± 0.19 fold, p = 0.02 and 1.43 ± 0.11
fold, p = 0.02 for two PML siRNAs, respectively). As
expected, TNFα potently promoted U937 cell adhesion
to HUVECs as shown in control siRNA transfected cells
(“siCtrl”, 14.18± 1.04 fold, p = 1.52× 10−6). Interestingly,
knockdown of PML signiﬁcantly decreased TNFα-
mediated induction of cell adhesion (only 5.54± 1.03 fold,
p = 0.0004 and 8.00 ± 0.62 fold, p = 0.0015 for two PML
siRNAs). Taken together, our data demonstrate that PML
and TNFα regulates cell adhesion in an interactive man-
ner and that PML is required for maximal TNFα-induced
leukocyte adhesion to HUVECs.
Discussion
The oﬀ-target eﬀects of siRNA
SiRNA is a commonly used approach to transiently knock
down expression from gene of interests to investigate
their function. However, some siRNAs have oﬀ-target
eﬀects. Indeed, our data (Figure 1a) showed that the over-
lapping aﬀected genes account for 63% and 68% of the
total aﬀected genes by two independent PML siRNAs
respectively. Our study suggests that careful evaluation of
siRNA by using more than one siRNAs is critical for data
analysis.
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The role of PML in class I MHC HLA expression
Our study found that PML is required for normal expres-
sion of a cluster of class I MHC HLAs, including
HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G as PML
knockdown signiﬁcantly reduced the expression of these
genes. Normal expression of class I HLAs is essential for
adaptive immune responses, cytotoxicity-mediated can-
cer cell removal, and precise modulation of inﬂamma-
tory responses. Loss or down-regulation of class I MHC
HLAs plays a causative role in etiology of these conditions
[17-22]. Because PML is down-regulated in many cancers
[9], we suspect the down-regulation of PML and thereby
class I MHC HLAs is one of the mechanisms used by can-
cers to escape the anti-tumor immune response. Thus,
PML likely maintains the expression levels of class I HLAs
as part of its tumor suppressor activity. Furthermore, class
I HLAs are often down-regulated by virus infection [23],
consistent with the notion that PML is an anti-viral pro-
tein. Loss of PML may increase the vulnerability to viral
infection [24]. Therefore, our analysis suggests that PML
is a putative novel regulator of class I HLAs and that PML
functions to reduce the susceptibility to cancers and other
diseases by controlling expression of downstream target
genes, including class I HLAs.
PML in metabolic control of cell physiology
Tumors have been known to alter metabolism pattern
since the description of the Warburg eﬀect [25]. Recent
studies have linked tumors with obesity. Obesity is also
a known risk factor for diabetes and cardiovascular dis-
eases. PML is known for its role as a tumor suppressor
protein; however its role in metabolism remains largely
unexplored. Our data suggest that PML is involved in
multiple aspects of cellular metabolic pathways involving
macromolecules, biopolymer, nitrogen compounds and
nucleotides. As we were preparing our manuscript, it
was reported that PML negatively regulates adipogenesis
[26]. When our manuscript was under review, we learned
that two latest papers reporting PML’s role in cancer
metabolism [27] and stem cell metabolism [28]. Therefore
the role of PML in cellular metabolism is an incomplete
understood questionworth further in-depth investigation.
PML inhibits cell adhesion and inﬂammatory response in
endothelial cells: PML’s role in vascular angiogenesis
unveiled
Endothelial cell has signiﬁcant relevance in angiogene-
sis, a critical process during embryology, cancer devel-
opment and cardiovascular diseases. Angiogenesis is a
series of multicellular morphological modiﬁcation involv-
ing cell adhesion, migration and diﬀerentiation [29].
Chronic inﬂammation usually promotes angiogenesis
[29-32]. Our data show that PML regulates multiple path-
ways involved in cell adhesion (Table 2 and Figure 5),
the inﬂammatory response following TNFα treatment
(Figure 4), and a molecular network of genes involved
in cell mobility (Additional ﬁle 3: Figure S2). Together,
our data suggest that PML is able to regulate several dif-
ferent aspects of angiogenesis. Indeed, PML has been
shown to inhibit hypoxia-mediated neoangiogenesis [33].
We have also recently demonstrated that PML is essential
for TNFα-mediated inhibition of endothelial cell network
formation and migration by regulating downstream tar-
get gene expression [15]. We believe that further study
on PML and TNFα target genes will shed a light on spe-
ciﬁc molecular mechanisms of angiogenesis in cancer and
human cardiovascular diseases.
The networks that are regulated by both PML knockdown
and TNFα treatment
TNFα signaling has been well-studied but remains to be
fully elucidated. Our study suggests that PML and TNFα
signaling regulates genes involved in a similar spectrum of
biological processes, molecular functions, cellular compo-
nents, canonical pathways, and human diseases (Figure 2,
Tables 2 and 3, and Figure 3). These analyses suggest that
there exists mutual regulatory networks between PML
and TNFα signaling. Indeed, we identiﬁed a set of NF-
κB-dependent genes that are uniquely regulated by PML
and TNFα signaling (Figure 4). We found that knockdown
of PML suppressed the expression of these genes in the
absence of TNFα treatment but enhanced their expres-
sion following TNFα treatment.We hypothesize that PML
functions as a molecular switch in TNFα signaling. As
such, we reason that the magnitude of PML accumula-
tion following TNFα treatment may have profound eﬀects
on TNFα activity and that ablation of PML gene may
lead to dysregulation of inﬂammatory responses. In fact,
our microarray analyses demonstrate that knockdown of
PML is associated with a network of genes involved in
chronic inﬂammation-related diseases, such as Rheuma-
toid arthritis and Atherosclerosis (Figure 3). In summary,
we have identiﬁed the genes induced by TNFα treatment
alone, the genes induced only when PML is knocked down
and the genes co-regulated by TNFα and PML knock-
down. We believe our results provide future directions in
the study of PML- and TNFα-coregulated inﬂammatory
responses.
Conclusions
Through microarray analyses, we identiﬁed novel PML
target genes and TNFα responsive genes in HUVEC.
Intriguingly, we found that PML is required for normal
expression of class I MHC HLAs, thereby suggesting a
potential novel mechanism by which PML functions as a
tumor suppressor. Our gene ontology information anal-
yses show that PML target genes and TNFα responsive
genes participated in a variety of overlapped and distinct
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biological processes, canonical pathways and human dis-
eases. Notably, we identiﬁed clusters of genes impli-
cated in inﬂammation-related diseases and TNFα-elicited
NF-κB-mediated immune responses that are synergis-
tically regulated by PML knockdown and TNFα treat-
ment. Our data further suggests that PML is a putative
novel TNFα regulator, required to ﬁnely control TNFα-
mediated inﬂammatory responses. Our study adds to the
understanding of TNFα biology and provides novel infor-
mation for potential pharmaceutical targets in TNFα-
related diseases. Through clustering analyses, we noticed
that the adhesion-related crosstalk between PML and
TNFα engages a complex molecular mechanism. Indeed,
our leukocyte adhesion assays demonstrated that the
eﬀects of PML knockdown could be switched from activa-
tion to inhibition of leukocyte adhesion depending on the
presence or absence of TNFα. Together, our results that
had not been previously appreciated have uncovered roles
of PML and its crosstalk with TNFα signaling.
Methods
Experimental design
A 3 × 2 factorial design was adapted. To study PML
gene function, we used an siRNA-mediated knockdown
approach. The siRNA factor had three levels: control
siRNA (siC, no knockdown) and two diﬀerent PML siR-
NAs (siP1 and siP2). The two PML siRNAs were used to
eliminate oﬀ-target eﬀects. TNFα treatment had two lev-
els: no treatment (U) and treatment (T). Each sample had
technical duplicates on diﬀerent microarray chips.
Sample preparation and the microarray
To prepare the samples, HUVECs (Lonza, C2519A, pas-
sage # < 5) were transfected with a control siRNA
(Dharmacon, D-001810-01) or two diﬀerent PML siRNAs
(Dharmacon, J-006547-05 and J-006547-07) for 72 h fol-
lowed by treatment with vehicle (water) or 20 ng/mL
TNFα for 20 h. Total RNA was extracted with a USB
PrepEase kit following the manufacturer’s instructions.
An aliquot of the total RNA was reverse transcribed into
cDNAs and veriﬁed by qRT-PCR and gel electrophore-
sis to ensure that the knockdown eﬃciency of PML was
greater than 75%. The mRNAs were reverse-transcribed
into biotin labeled cRNAs with the MessageAMP II kit
(Ambion) prior to the microarray hybridization with
Human Reference Sequence-8 Version 2 Expression Bead-
Chip (Illumina, HumanRef-8 V2 0 R0 11223162 A). The
probe-level raw data with background noise subtracted
were used for statistical analyses. The quality controls
of our microarray are shown in supplementary data
(Additional ﬁle 3: Figure S3). The microarray was pro-
cessed by Genomics Core Facility at Cleveland Clinic
Foundation. The background-subtracted raw data is
enclosed as Additional ﬁle 4.
Data preprocessing, gene lists and functional analyses
Themicroarray data were analyzed in the R/Bioconductor
environment [34,35]. Brieﬂy, the raw data were prepro-
cessed with the lumi package [36,37]. The probe quality
was assessed by detection p-values. Those probes with
non-signiﬁcant detection p-values (p > 0.1) in all samples
were removed prior to analyses. The data was transformed
by a Variance-Stabilizing Transformation (VST) package
[38] and normalized by a Robust Spline Normalization
(RSN) package [38]. Using the Linear Models for Microar-
ray Data (LIMMA) package [39] and empirical Bayes
method with the false discovery rate (FDR) adjusted by the
Benjamini and Hochberg’s method, we retrieved the sig-
niﬁcantly changed gene lists (> 1.5 fold and FDR adjusted
p (q) < 0.05). The samples treated by two diﬀerent
PML siRNAs were considered as independent biologi-
cal samples to retrieve gene lists. The PML knockdown
aﬀected gene list was generated by averaging the com-
monly aﬀected genes by both PML siRNAs. Hierarchical
clustering with average linkage was used to for the cluster
analysis. Sub-clusters were identiﬁed by the dynamicTree-
Cut R package [40]. For functional ontology analyses,
we used the hypergeometric test through the GeneAn-
swers package [41]. The chromosomal pattern of altered
genes were analyzed byMicroArray Chromosome Analysis
Tool (MACAT) package [42]. The clustering analyses with
ontology information was done by TEASE (Tree-Ease) in
the MultiExperiment Viewer (MeV v4.8, an R-based soft-
ware). The proﬁle of signiﬁcantly aﬀected genes is shown
as a heatmap in supplementary data (Additional ﬁle 3:
Figure S4).
Cell adhesion assays
Cell adhesion assays were carried out with an endothe-
lial cell adhesion assay kit (Millipore, ECM645) according
to the manufacturer’s instructions. Brieﬂy, HUVECs were
transfected with a control non-targeting siRNA or two
diﬀerent PML siRNAs and equally seeded in a 96-well
plate until a monolayer of conﬂuent cells was reached.
The resulting monolayer of HUVECs were treated with
20 ng/mL TNFα for 4 h, prior to 30-min incubation
with U937 human leukocyte cells pre-labeled with Calcein
AM®. The plate was washed extensively and the adher-
ent U937 cells were quantiﬁed by reading ﬂuorescence of
485nm/530nm on a microplate reader.
Additional ﬁles
Additional ﬁle 1: Gene lists. An excel spreadsheet containing the
signiﬁcantly aﬀected gene lists and the ontology annotation information.
Additional ﬁle 2: Aﬀected categories of gene ontology. An excel
spreadsheet containing the signiﬁcantly aﬀected gene ontology categories.
Additional ﬁle 3: Supplemental data. A PDF ﬁle contains: supplemental
materials and methods; Figure S1, the chromosomal
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analysis of PML target genes; Figure S2, the molecular network of PML
target genes related to cell mobility and cytokine/chemokine signaling.
Figure S3, the quality controls of microarray samples Figure S4, the
heatmap and subclusters of the signiﬁcantly aﬀected genes by PML
knockdown and TNFα treatment;
Additional ﬁle 4: Raw data. An excel spreadsheet containing the
background-subtracted probe level raw data.
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